| 289 | Assessing and managing emerging AAV-related toxicities after gene therapy for neuromuscular disorders | 26 September 2025 | |
| 288 | Towards better diagnosing, understanding and treating gastrointestinal symptoms in myotonic dystrophy | 16 May 2025 | |
| 287 | Harmonization and federated analysis of myotonic dystrophy registries to model heterogeneous disease trajectories | 28 March 2025 | |
| 286 | Muscle Imaging: Artificial Intelligence, Automatic Segmentation and Imaging Data Sharing in Neuromuscular Disease | 7 March 2025 | |
| 285 | SMN-related neurodevelopmental disorder: type 1 Spinal Muscular Atrophy and the brain | 31 January 2025 | |
| 284 | Cognitive and behavioral abnormalities in pediatric DM1 – what should we measure in preparation for clinical trials? | 24 January 2025 | |
| 283 | Establishing Expert Care Recommendations for LAMA2-RDs: A Prototype for the Development of Congenital Muscular Dystrophy Subtype-Specific Care Guidelines | 17 January 2025 | |
| 280 | Diagnostic criteria and outcome measures in primary mitochondrial myopathies | 22 November 2024 | |
| 282 | Standards of diagnosis and care for the Sarcoglycanopathies | 8 November 2024 | 2002 |
| 279 | Classification, clinical care, outcome measures and biomarkers in childhood onset FSHD: towards standardising clinical care and ensuring clinical trial readiness. | 1 November 2024 | |
| 281 | 2nd ENMC workshop on exercise training in muscle diseases; towards consensus-based recommendations on exercise prescription and outcome measures. | 4 October 2024 | |
| 278 | European standards for harmonization of myasthenia gravis registries and emerging digital solutions | 20 September 2024 | |
| 277 | Congenital myopathies: revising and revisiting nomenclature and diagnostic guidelines | 21 June 2024 | |
| 276 | ENMC recommendations on optimal diagnostic pathway and management strategy for patients with rhabdomyolysis worldwide. | 15 March 2024 | |
| 275 | Seronegative MG: An update paradigm for diagnosis and management | 9 February 2024 | |
| 274 | ENMC recommendations for optimizing bone strength in neuromuscular disorders | 19 January 2024 | |
| 273 | Clinico-Sero-Morphological Classification of the Antisynthetase Syndrome (ASyS) – Associated Myositis | 27 October 2023 | |
| 271 | Third ENMC meeting on SBMA: Towards a unifying effort to fight Kennedy’s Disease | 20 October 2023 | |
| 272 | Inclusion Body Myositis: 10 years of progress – revision of the ‘ENMC 2013 diagnostic criteria for IBM’ and trial readiness | 16 June 2023 | |
| 270 | Consensus for SMN2 genetic analysis in SMA patients | 10 March 2023 | |
| 269 | Clinical trials in DMD: Ten years on, what have we learned? How can we optimize future trial design? | 9 December 2022 | |
| 268 | Genetic diagnosis, clinical classification, outcome measures, and biomarkers in Facioscapulohumeral Muscular Dystrophy (FSHD): relevance for clinical trials | 30 September 2022 | |
| 255 | Muscle Imaging in idiopathic inflammatory myopathies virtual meetings, first (15-16 January 2021) second (22 January 2021) third -hybrid- (9 – 10 September 2022) | 9 September 2022 | |
| 262 | Standards of care for the Dysferlinopathies | 4 July 2022 | |
| 253 | Skeletal muscle laminopathies – natural history and clinical trial readiness, first (30-31 October 2020), second (19-20 February 2021), third (10 December 2021) and fourth meeting (24-26 June 2022) | 30 June 2022 | |
| 261 | Management of safety issues arising follosing AAV gene therapy, first (19 March 2021), second (17-19 June 2022) | 19 June 2022 | |
| 257 | The 3rd ENMC workshop on Dystroglycan and the Dystroglycanopathies | 10 June 2022 | |
| 263 | Focus on female carriers of dystrophinopathy: refining recommendations for prevention, diagnosis, surveillance and treatment. Virtual meetings: first (25 June 2021), second (26 November 2021), third -hybrid- (13-15 May 2022) | 25 May 2022 | |
| 267 | Psychological Interventions for improving quality of life in slowly progressive neuromuscular disorders | 20 May 2022 | |
| 265 | Muscle Imaging in Facioscapulohumeral Muscular Dystrophy (FSHD): relevance for clinical trials | 22 April 2022 | |
| 258 | Genetic Epidemiology and Clinical Trial Readiness in Encephalomyopathy of Leigh Syndrome Spectrum, virtual meetings; first (16 October 2020) second (4 December 2020) third (9 July 2021) fourth -hybrid- meeting (25 – 27 March 2022) | 9 April 2022 | |
| 266 | Remote delivery of clinical care and validation of remote clinical outcomes in neuromuscular disorders: a response to COVID-19 and proactive planning for the future | 1 April 2022 | |
| 260 | Congenital Myasthenic Syndromes | 11 March 2022 | |
| 254 | Formation of a European network to initiate a European data collection, along with development and sharing of treatment guidelines for adult SMA patients | 28 January 2022 | |
| 256 | Myositis specific and associated autoantibodies (MSA-ab) | 24 November 2021 | |
| 264 | Multi-system involvement in Spinal Muscular Atrophy | 19 November 2021 | |
| 259 | Anaesthesia and neuromuscular disorders, first (11 December 2021), second (28-29 May 2021) | 28 May 2021 | |
| 252 | Developing best practice guidelines for management of mouthpiece ventilation in Neuromuscular Disorders | 23 March 2020 | |
| 251 | Polyglucosan storage myopathies | 13 December 2019 | |
| 249 | The role of brain dystrophin in muscular dystrophy; Implications for clinical care and translational research | 29 November 2019 | |
| 248 | Myotonic dystrophies, molecular approaches for clinical purposes. Framing a European molecular research network | 11 October 2019 | |
| 247 | Muscle Magnetic Imaging: Implementing muscle MRI as a diagnostic tool for rare genetic myopathy cohorts | 20 September 2019 | |
| 250 | Clinical trial readiness in nemaline myopathy | 6 September 2019 | |
| 246 | Protein Aggregate Myopathies (PAM) | 24 May 2019 | |
| 244 | Newborn screening in Spinal Muscular Atrophy | 10 May 2019 | |
| 243 | Developing guidelines for management of reproductive options for families with maternally inherited mtDNA disease | 22 March 2019 | 2019 |
| 242 | Diagnosis and Management of Juvenile Myasthenia Gravis | 1 March 2019 | 2019 |
| 241 | Towards a European Unifying lab for Kennedy’s disease | 15 February 2019 | 2019 |
| 240 | The involvement of skeletal muscle stem cells in the pathology of muscular dystrophies | 25 January 2019 | 2019 |
| 239 | Clinicopathological Classification of Dermatomyositis | 14 December 2018 | 2018 |
| 245 | Euro-NMD Pathology | 7 December 2018 | 2018 |
| 238 | Updating management recommendations of cardiac dystrophinopathy | 30 November 2018 | 2018 |
| 237 | GNE myopathy (GNEM) | 14 September 2018 | 2018 |
| 236 | Bone Protective Therapy in Duchenne MD | 1 June 2018 | 2018 |
| 235 | The position of neuromuscular patients in Shared-Decision-Making (SDM) | 19 January 2018 | 2018 |
| 234 | Chaperone Dysfunction in muscle disease | 8 December 2017 | 2017 |
| 233 | Clinical trial readiness for Calpainopathies | 15 September 2017 | 2017 |
| 232 | Recommendations for treatment of Mitochondrial DNA maintenance disorders | 16 June 2017 | 2017 |
| 231 | International standard for CIDP registry and biobank | 12 May 2017 | 2017 |
| 229 | Limb Girdle Muscular Dystrophies, Nomenclature and reformed Classification | 17 March 2017 | 2017 |
| 228 | Airway clearance techniques in Neuromuscular Disorders | 3 March 2017 | 2017 |
| 230 | Improving future assessment and research in IgM anti-MAG peripheral neuropathy; a consensus collaborative effort | 24 February 2017 | 2017 |
| 227 | Finalizing a plan to guarantee quality in translational research for Neuromuscular diseases | 10 February 2017 | 2017 |
| 226 | Towards validated and qualified biomarkers for therapy development for Duchenne Muscular Dystrophy | 30 January 2017 | 2017 |
| 225 | A global FSHD registry framework | 18 November 2016 | 2016 |
| 224 | Clinicopathological classification of Immune-mediated necrotizing myopathies | 14 October 2016 | 2016 |
| 223 | AAV Microdystrophin gene therapy for DMD | 16 September 2016 | 2016 |
| 222 | Myotonic Dystrophy – Developing a European Consortium for Care and Therapy | 1 July 2016 | 2016 |
| 221 | Foot surgery in Charcot-Marie-Tooth disease | 10 June 2016 | 2016 |
| 220 | The 2nd ENMC workshop on Dystroglycan and the Dystroglycanopathies | 27 May 2016 | 2016 |
| 219 | Titinopathies – International database of TTN mutations and phenotypes | 29 April 2016 | 2016 |
| 218 | Revisiting the consensus statement for standards of care in SMA | 19 February 2016 | 2016 |
| 217 | RYR-1 related myopathies | 29 January 2016 | 2016 |
| 216 | Clinical trial readiness for FKRP related muscular dystrophies | 15 January 2016 | 2016 |
| 215 | VCP-related multi-system proteinopathy | 27 November 2015 | 2015 |
| 214 | Establishing an international consortium for gene discovery and clinical research for Congenital Muscle Diseases | 16 October 2015 | 2015 |
| 213 | Outcome measures and clinical trial readiness in Idiopathic Inflammatory Myopathies (IIM) | 18 September 2015 | 2015 |
| 212 | Animal models in CMD | 29 May 2015 | 2015 |
| 211 | Development of diagnostic criteria and management strategies for McArdle Disease and related rare glyco(geno)lytic disorders to improve standards of care | 17 April 2015 | 2015 |
| 210 | Towards a European consortium for research and patient clinical management in Spinal and Bulbar Muscular Atrophy (SBMA) | 27 March 2015 | 2015 |
| 209 | SMA outcomes and clinical trial readiness | 7 November 2014 | 2014 |
| 208 | Formation of a European network to develop a European data sharing model and treatment guidelines for Pompe disease | 6 October 2014 | 2014 |
| 207 | Chronic respiratory insufficiency in Myotonic Dystrophies: management and implications for research | 21 July 2014 | 2014 |
| 206 | Adults with DMD | 23 May 2014 | 2014 |
| 205 | Pathology Diagnosis of Idiopathic Inflammatory Myopathies | 1 April 2014 | 2014 |
| 204 | Biomarkers in DMD | 13 February 2014 | 2014 |
| 203 | Respiratory Pathophysiology in Congenital Onset Neuromuscular Disease: Implications for Pro-active Care and Clinical Research | 19 December 2013 | 2013 |
| 202 | Clinical Characteristics, Pathomechanisms and Trial Design for Calpainopathy (LGMD2A) | 21 November 2013 | 2013 |
| 201 | Autophagy in Muscular Dystrophies: Translational approach | 8 November 2013 | 2013 |
| 200 | European Reference Networks (ERN) – recommendations and criteria in the Neuromuscular field | 18 October 2013 | 2013 |
| 199 | FHL1 related myopathies: towards an FHL1 related myopathy consortium | 6 June 2013 | 2013 |
| 198 | Centronuclear Myopathies | 31 May 2013 | 2013 |
| 197 | Neuromuscular disorders of mitochondrial fusion and fission – Molecular mechanisms and therapeutic strategies | 26 April 2013 | 2013 |
| 196 | Outcome Measures in inflammatory peripheral neuropathies (PeriNoms) | 1 February 2013 | 2013 |
| 195 | Newborn screening for DMD | 12 December 2012 | 2012 |
| 194 | Towards clinical applications of antisense-mediated exon skipping for DMD | 10 December 2012 | 2012 |
| 193 | Pathology Diagnosis of Idiopathic Inflammatory Myopathies | 2 December 2012 | 2012 |
| 192 | ENMC Strategic workshop, shaping a stronger future | 18 June 2012 | 2012 |
| 191 | Recent advances in OPMD research | 11 June 2012 | 2012 |
| 190 | SMARD type 1 | 13 May 2012 | 2012 |
| 189 | Complex I Deficiency | 22 April 2012 | 2012 |
| 188 | Inclusion Body Myositis | 5 December 2011 | 2011 |
| 187 | Dystroglycan and Dystroglycanopathies | 17 November 2011 | 2011 |
| 186 | Congenital Myasthenic Syndromes | 27 June 2011 | 2011 |
| 185 | Stem/Precursor cells | 8 June 2011 | 2011 |
| 184 | Pain and Fatigue in NMD, Prevalence and management | 23 May 2011 | 2011 |
| 183 | Pre-clinical studies in animal models of Charcot-Marie-Tooth | 10 May 2011 | 2011 |
| 182 | RYR1 related myopathies | 18 April 2011 | 2011 |
| 181 | Ongoing updating and dissemination of standards of care for DMD | 13 December 2010 | 2010 |
| 180 | Myotonic Dystrophy type 2 (DM2) | 6 December 2010 | 2010 |
| 179 | Pregnancy in women with NMD | 8 November 2010 | 2010 |
| 178 | ALS | 4 October 2010 | 2010 |
| 177 | Pompe disease | 12 September 2010 | 2010 |
| 176 | Diagnosis and treatment of Co enzyme Q10 deficiency | 12 July 2010 | 2010 |
| 175 | Mitochondrial protein synthesis in health and disease | 28 June 2010 | 2010 |
| 174 | Applying Pre-implantation Genetic Diagnosis to mtDNA Diseases | 22 March 2010 | 2010 |
| 173 | Congenital Muscular Dystrophy (CMD) Outcome measures | 21 March 2010 | 2010 |
| 172 | Dysferlinopathy | 31 January 2010 | 2010 |
| 171 | Standards of care and the management of FSHD patients | 9 January 2010 | 2010 |
| 170 | Bone protection for DMD patients taking corticosteroids | 30 November 2009 | 2009 |
| 169 | Rare Structural Congenital Myopathies | 9 November 2009 | 2009 |
| 168 | Outcome Measures and Clinical trials in CHARCOT-MARIE-TOOTH DISEASE | 20 September 2009 | 2009 |
| 167 | X-linked myopathy with excessive autophagy (XMEA) | 22 June 2009 | 2009 |
| 166 | Collagen VI related myopathies | 25 May 2009 | 2009 |
| 165 | Distal Myopathies | 10 February 2009 | 2009 |
| 164 | Centro Nuclear Myopathy | 16 January 2009 | 2009 |
| 163 | Mitochondrial DNA Disorders | 12 December 2008 | 2008 |
| 162 | Disorders of muscle lipid metabolism in adults | 30 November 2008 | 2008 |
| 0 | Guidelines for DMD Genetic testing | 16 November 2008 | 2008 |
| 0 | MRI in muscle diseases | 19 October 2008 | 2008 |
| 161 | Nemaline Myopathy and related disorders | 29 September 2008 | 2008 |
| 160 | Exercise training in patients with muscle diseases | 23 June 2008 | 2008 |
| 159 | 4th Annual Plenary meeting EUMITOCOMBAT | 27 March 2008 | 2008 |
| 158 | XIIth International workshop on Congenital Muscular Dystrophy | 11 February 2008 | 2008 |
| 157 | Patient registries of rare, inherited muscular disorders | 28 January 2008 | 2008 |
| 156 | Desmin and Protein Aggregate Myopathies | 22 November 2007 | 2007 |
| 155 | Polymerase gamma and disorders of mitochondrial DNA synthesis | 2 October 2007 | 2007 |
| 154 | TREAT-NMD workshop on Outcome Measures for Experimental Studies in DMD | 2 July 2007 | 2007 |
| 153 | 3rd Annual Plenary Meeting EUMITOCOMBAT | 27 June 2007 | 2007 |
| 152 | European Spinal Muscular Atrophy Randomized Clinical Trial II (EUROSMART II) | 20 June 2007 | 2007 |
| 151 | International Inflammatory Neuropathy Consortium | 19 April 2007 | 2007 |
| 150 | Core Myopathies | 2 April 2007 | 2007 |
| 149 | Planning Phase I/II Clinical trials Using Systemically Delivered AON in DMD | 28 March 2007 | 2007 |
| 148 | European Amyotrophic lateral sclerosis (EURALS) | 9 February 2007 | 2007 |
| 147 | Guideline on processing and evaluation of Sural Nerve Biopsies | 24 December 2006 | 2006 |
| 146 | Recent advances in Fibrodysplasia Ossificans Progressiva (FOP) | 7 November 2006 | 2006 |
| 145 | Planning for an international trial of steroid dosage regimes in DMD | 6 November 2006 | 2006 |
| 144 | Outcome Measures in McArdle Disease | 16 October 2006 | 2006 |
| 143 | 2nd Annual Plenary Meeting EUMITOCOMBA | 21 May 2006 | 2006 |
| 142 | Guidelines on Preclinical studies in ALS | 24 April 2006 | 2006 |
| 141 | EURO-laminopathies Kick-off meeting | 10 March 2006 | 2006 |
| 140 | 140th ENMC International Workshop: DM2 and other myotonic dystrophies | 20 January 2006 | 2006 |
| 139 | EUMITOCOMBAT International Workshop – 1st Plenary Meeting | 2 June 2005 | 2005 |
| 138 | Nemaline Myopathy | 20 May 2005 | 2005 |
| 137 | Pompe Disease/GSDII | 22 April 2005 | 2005 |
| 136 | Charcot-Marie-Tooth disease Type 1A | 8 April 2005 | 2005 |
| 135 | Nutrition in ALS | 8 March 2005 | 2005 |
| 134 | Outcome Measures and Treatment of Spinal Muscular Atrophy | 11 February 2005 | 2005 |
| 133 | Congenital Muscular Dystrophy (CMD) | 21 January 2005 | 2005 |
| 132 | Planning steroid dosage trials in DMD | 3 January 2005 | 2005 |
| 131 | The Selection of Outcome Measures for Peripheral Neuropathy Clinical Trials | 10 December 2004 | 2004 |
| 130 | Kick-off meeting EUMITOCOMBAT | 12 November 2004 | 2004 |
| 129 | Randomised trials of treatment for chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy | 27 October 2004 | 2004 |
| 128 | Antisense Oligonucleotides in Duchenne Muscular Dystrophy | 22 October 2004 | 2004 |
| 127 | Implementation of European Registry of ALS | 8 October 2004 | 2004 |
| 126 | Congenital Myasthenic Syndromes | 24 September 2004 | 2004 |
| 125 | Neuromuscular disorders in gypsies | 23 April 2004 | 2004 |
| 124 | Treatment of Duchenne Muscular Dystrophy | 2 April 2004 | 2004 |
| 123 | Management and therapy of myotonic dystrophy (II) | 6 February 2004 | 2004 |
| 122 | Inducing muscle hypertrophy as a therapeutic strategy for muscular dystrophies | 28 November 2003 | 2003 |
| 121 | DESMIN and Protein Aggregate MyopathiesDESMIN and Protein Aggregate Myopathies | 7 November 2003 | 2003 |
| 120 | Clinical Trials of Minocycline in Amyotrophic Lateral Sclerosis (ALS) | 24 October 2003 | 2003 |
| 119 | Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis | 10 October 2003 | 2003 |
| 118 | Advances in Myotubular Myopathy | 26 September 2003 | 2003 |
| 117 | Ventilatory Support in Congenital Neuromuscular Disorders: Congenital Myopathies, Congenital Muscular Dystrophies, Congenital Myotonic Dystrophy and SMA (II) | 4 April 2003 | 2003 |
| 116 | Treatment of mitochondrial disease | 14 March 2003 | 2003 |
| 115 | DM2/PROMM and other myotonic dystrophies | 14 February 2003 | 2003 |
| 114 | Congenital Muscular Dystrophy (CMD) | 17 January 2003 | 2003 |
| 113 | EUMITOCOMBAT | 14 December 2002 | 2002 |
| 112 | Bethlem Myopathy and other diseases related to collagen type VI | 8 November 2002 | 2002 |
| 111 | Multi-minicore Disease | 8 November 2002 | 2002 |
| 110 | Congenital non-progressive Ocular Neuromuscular Disorders | 25 October 2002 | 2002 |
| 109 | Nemaline Myopathy | 11 October 2002 | 2002 |
| 108 | 3rd Workshop of the MYOCLUSTER project: EUROMEN | 13 September 2002 | 2002 |
| 107 | The management of cardiac complications in muscular dystrophy and myotonic dystrophy | 7 June 2002 | 2002 |
| 106 | Non-Invasive positive Pressure Ventilation (NIPPV) in Amyotrophic Lateral Sclerosis (ALS) | 3 May 2002 | 2002 |
| 105 | Limb-girdle muscular dystrophy – exploring the pathophysiology of the non-sarcoglycan types of limb-girdle muscular dystrophy | 12 April 2002 | 2002 |
| 104 | Distal myopathies | 8 March 2002 | 2002 |
| 103 | Designing rational therapy of SMA based on understanding of its pathophysiology | 18 January 2002 | 2002 |
| 102 | Advances in Schwartz-Jampel syndromes | 14 December 2001 | 2001 |
| 101 | Therapeutic possibilities in Duchenne dystrophy | 30 November 2001 | 2001 |
| 100 | Bethlem Myopathy and other diseases related to collagen Type VI | 23 November 2001 | 2001 |
| 99 | Myotonic dystrophy: present management, future therapy | 9 November 2001 | 2001 |
| 98 | Congenital Muscular Dystrophy (CMD) | 28 October 2001 | 2001 |
| 97 | 2nd Workshop of the MYO CLUSTER project: EUROMEN | 28 September 2001 | 2001 |
| 96 | DESMIN – Protein Surplus Myopathies | 14 September 2001 | 2001 |
| 95 | Cognitive Impairment in Neuromuscular Disorders | 13 July 2001 | 2001 |
| 94 | Basic methodologies for clinical trials in myopathies | 11 May 2001 | 2001 |
| 93 | Non 5q-spinal muscular atrophy (SMA) | 6 April 2001 | 2001 |
| 92 | Therapy for the periodic paralyses (2) | 23 March 2001 | 2001 |
| 91 | NMD in Gypsies | 9 March 2001 | 2001 |
| 90 | Spinal Muscular Atrophy | 9 February 2001 | 2001 |
| 89 | Central Core Disease (CCD) | 9 January 2001 | 2001 |
ENMC attended the WMS congress23 October 2025 - 11:10
ENMC Impact Report 2024 is NOW available!3 June 2025 - 12:33
ENMC APPROVED 4 WORKSHOP APPLICATIONS26 May 2025 - 11:30
TREAT-NMD – new ENMC Associated Partner23 January 2025 - 13:50
ENMC approved 3 workshop applications!16 December 2024 - 13:01